ClinicalTrials.gg
TerminatedNCT00632203Updated Jun 7, 2017Results posted

Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)

A Phase 2 interventional study of Temozolomide in Carcinoma, Non-Small-Cell Lung, Adenocarcinoma and Carcinoma, Large Cell, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing temozolomide in Carcinoma, Non-Small-Cell Lung — none open to participants now, none under way, none of them phase 3. Temozolomide · Carcinoma, Non-Small-Cell Lung.

Enrollment
9th of 16
53 · median 56
Started
2008
with 1 other
Phase 2
12 of 16
none open now
Registered
13th of 16
by date
Lead sponsor
6 of 16
Merck Sharp & Dohme LLC

Among the 16 studies testing temozolomide in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment, is one of 2 that started in 2008, is one of 12 in phase 2, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 16 studies testing temozolomide in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing temozolomide in Carcinoma, Non-Small-Cell Lung as a file.
02

Study summary

The main objective of this study is to investigate whether administration of maintenance temozolomide following standard treatment could possibly prevent or delay the onset of brain metastases in patients with controlled non-small cell lung cancer (NSCLC).

Read the detailed description

This is a Phase 2, open-label, randomized, multicenter study of maintenance temozolomide versus observation in subjects with stable or responding stage III/IV NSCLC to be conducted in conformance with Good Clinical Practices. Subjects will be randomly assigned to a study drug (temozolomide) or observation arm. The study drug will be administered at a dose of 75 mg/m\^2 PO daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first. Subjects completing 6 cycles of treatment will be followed up for incidence of brain metastasis for up to 2 years, or until progression.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
  • Adenocarcinoma
  • Carcinoma, Large Cell
  • Carcinoma, Squamous Cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects (age >=18 years), of either sex, and of any race.
  • Subjects must have stage IV or III with pleural and/or pericardial effusion

confirmed NSCLC.

  • Subjects must have completed 2-6 cycles of a standard systemic therapy, with or without radiation therapy, consisting of at least 2 anti-tumor agents as treatment for Stage III/IV disease, and have documented complete response (CR), partial response (PR), or stable disease (SD) per (RECIST).
  • Response must be confirmed within 4-8 weeks of completing first-line chemotherapy. Study treatment must begin within 12 weeks of completing first-line chemotherapy.
  • Female subjects of or male subjects with female partner of childbearing potential must agree to use a medically accepted method of or be surgically sterilized prior to Screening, while receiving study drug, and for 30 days after stopping study drug. Female subjects of childbearing potential must have a negative pregnancy test confirmed prior to dosing with study drug.
  • Subjects must be free of any disease (other than stage III/IV NSCLC) that would, in the principal investigator and/or Sponsor's opinion, interfere with the conduct of the study or study evaluations.
  • Subjects must be able to adhere to the dosing and visit schedules, and agree to report medication taken, concomitant medications, and adverse events (AEs).
  • (ECOG) performance status \<=2.
  • Clinical laboratory tests (complete blood count [CBC], serum chemistries) must be obtained within 14 days prior to randomization and meet specified criteria.

Exclusion criteria

Exclusion Criteria:

  • documented on post-chemotherapy magnetic resonance imaging (MRI).
  • Documented history of brain metastases.
  • Subject has received more than one prior anti-tumor regimen for Stage III/IV disease. "Regimen" refers to single drug or planned combination of two or more anti-tumor therapies. Bevacizumab (Avastin®) as part of a planned sequence of therapy after platinum-containing double regimen is not considered a second regimen. treatment for resectable subjects is not considered a second regimen.
  • Subject has used any product within 4 weeks prior to enrollment.
  • Subject is currently receiving immunotherapy or chemotherapy, cytotoxic or targeted therapy as treatment for active systemic disease. Bevacizumab (Avastin®) as part of the prescribed standard first-line regimen is allowed.
  • Female who is pregnant, or intends to become pregnant, during the study.
  • Subject is in a situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
  • Subject is currently participating in any other clinical study, with the exception of observational long-term follow-up.
  • Subject is allergic to, or has sensitivity to, the study drug or its .
  • Documented symptomatic, progressive or new bone following the first-line chemotherapy with or without radiation therapy (biphosphonate use for prophylaxis or as a maintenance therapy is allowed).
  • No prior except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the subject has been disease-free for 5 years.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Temozolomide treatment

    Subjects will receive temozolomide at a dose of 75 mg/m\^2 orally (PO) daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.

    Drug: Temozolomide

  • No intervention
    Observation

    Observation

Interventions

  • 5-mg, 20-mg, and 100-mg gel capsules, 75 mg/m\^2 PO daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.

    Also known as: Temodar®, SCH 52365

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Had Brain Metastases

    Brain Metastases were defined as radiological evidence of brain metastases on magnetic resonance imaging (MRI).

    Time frame: Up to 12 months (as measured from day 1 of cycle 1 of standard first-line systemic chemotherapy)

Secondary outcomes

  1. Time to Radiological Central Nervous System (CNS) Progression

    Defined as CNS progression as measured by MRI. Time to CNS progression was analyzed using the Kaplan-Meier method.

    Time frame: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to radiological progression or the last known CNS progression-free date

  2. Time to Progression

    The time to progression (per response evaluation criteria in solid tumors \[RECIST\]) was analyzed using the Kaplan-Meier method. Definitions of response per RECIST: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): A decrease of at least 30% in the sum of the longest diameter of target lesions. Progressive Disease (PD): An increase of at least 20% in the sum of the longest diameter of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

    Time frame: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to progression or up to 6 cycles (168 days) of study treatment

  3. Overall Survival

    The overall survival was analyzed using the Kaplan-Meier method.

    Time frame: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up

  4. Number of Participants With Brain Metastases at First Progression

    Brain Metastases were defined as radiological evidence of brain metastases on MRI.

    Time frame: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up (up to 6 cycles (168 days) of study treatment)

  5. Cancer-related Quality of Life (QoL) as Assessed by The European Organization for Research and Treatment of Cancer (EORTC) QoL Questionnaire C30 Version 3.0 (QLQ-C30), and the EORTC Lung Cancer Module (QLQ-LC13)

    The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Scores range from 0 -100. For functional and global QoL scales, higher scores mean a better level of function. For symptom-oriented scales, a higher score means more severe symptoms and a decrease in QoL. The EORTC QLQ-LC13 is a 13-item questionnaire developed to supplement the EORTC QLQ-C30 in lung cancer patients. It has a score range 0-100 with higher scores representing an increase in symptoms.

    Time frame: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up (up to 6 cycles (168 days) of study treatment)

  6. Tolerability of Maintenance Temozolomide

    Tolerability was defined as number of participants with any adverse event leading to study discontinuation and/or study drug discontinuation.

    Time frame: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up (up to 6 cycles (168 days) of study treatment)

07

Results

Posted Mar 26, 2012
Limitations and caveats
The interpretation of the study results should be taken with caution because of the small sample size due to early termination.

Participant flow

Participant flow — Overall Study
MilestoneTemozolomide TreatmentObservation
Started2627
Completed2527
Not completed10
Withdrew: Did not start study treatment10

Outcome measures

PrimaryNumber of Participants Who Had Brain Metastases

Brain Metastases were defined as radiological evidence of brain metastases on magnetic resonance imaging (MRI).

Time frame:
Up to 12 months (as measured from day 1 of cycle 1 of standard first-line systemic chemotherapy)
Reported as:
Number · participants
Number of Participants Who Had Brain Metastases
participantsTemozolomide TreatmentObservation
Number of Participants Who Had Brain Metastases43
Statistical analysis
  • Temozolomide Treatment vs Observation · 2-sided Exact Pearson Chi-square Test · p = 0.6995
SecondaryTime to Radiological Central Nervous System (CNS) Progression

Defined as CNS progression as measured by MRI. Time to CNS progression was analyzed using the Kaplan-Meier method.

Time frame:
from Cycle 1 Day 1 of Standard First Line Systemic Therapy to radiological progression or the last known CNS progression-free date
Reported as:
Median · months
Time to Radiological Central Nervous System (CNS) Progression
monthsTemozolomide TreatmentObservation
Time to Radiological Central Nervous System (CNS) ProgressionNA (14.26 to NA)NA (NA to NA)
SecondaryTime to Progression

The time to progression (per response evaluation criteria in solid tumors \[RECIST\]) was analyzed using the Kaplan-Meier method. Definitions of response per RECIST: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): A decrease of at least 30% in the sum of the longest diameter of target lesions. Progressive Disease (PD): An increase of at least 20% in the sum of the longest diameter of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

Time frame:
from Cycle 1 Day 1 of Standard First Line Systemic Therapy to progression or up to 6 cycles (168 days) of study treatment
Reported as:
Median · months
Time to Progression
monthsTemozolomide TreatmentObservation
Time to Progression11.70 (9.03 to 15.80)10.68 (8.54 to 12.68)
SecondaryOverall Survival

The overall survival was analyzed using the Kaplan-Meier method.

Time frame:
from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up
Reported as:
Median · months
Overall Survival
monthsTemozolomide TreatmentObservation
Overall Survival27.14 (13.90 to NA)22.54 (14.52 to NA)
SecondaryNumber of Participants With Brain Metastases at First Progression

Brain Metastases were defined as radiological evidence of brain metastases on MRI.

Time frame:
from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up (up to 6 cycles (168 days) of study treatment)

No measurements were reported for this outcome.

SecondaryCancer-related Quality of Life (QoL) as Assessed by The European Organization for Research and Treatment of Cancer (EORTC) QoL Questionnaire C30 Version 3.0 (QLQ-C30), and the EORTC Lung Cancer Module (QLQ-LC13)

The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Scores range from 0 -100. For functional and global QoL scales, higher scores mean a better level of function. For symptom-oriented scales, a higher score means more severe symptoms and a decrease in QoL. The EORTC QLQ-LC13 is a 13-item questionnaire developed to supplement the EORTC QLQ-C30 in lung cancer patients. It has a score range 0-100 with higher scores representing an increase in symptoms.

Time frame:
from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up (up to 6 cycles (168 days) of study treatment)

No measurements were reported for this outcome.

SecondaryTolerability of Maintenance Temozolomide

Tolerability was defined as number of participants with any adverse event leading to study discontinuation and/or study drug discontinuation.

Time frame:
from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up (up to 6 cycles (168 days) of study treatment)
Reported as:
Number · participants
Tolerability of Maintenance Temozolomide
participantsTemozolomide TreatmentObservation
Tolerability of Maintenance Temozolomide5NA

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Temozolomide Treatment—8/26 (30.8%)25/26 (96.2%)
Observation—4/27 (14.8%)24/27 (88.9%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventTemozolomide TreatmentObservation
DISEASE PROGRESSIONGeneral disorders0/262/27
DYSPNOEARespiratory, thoracic and mediastinal disorders1/262/27
LYMPHOPENIABlood and lymphatic system disorders1/260/27
PYREXIAGeneral disorders1/260/27
PNEUMONIAInfections and infestations1/260/27
DEHYDRATIONMetabolism and nutrition disorders1/260/27
HYPONATRAEMIAMetabolism and nutrition disorders1/260/27
BACK PAINMusculoskeletal and connective tissue disorders1/260/27
COGNITIVE DISORDERNervous system disorders1/260/27
DYSARTHRIANervous system disorders1/260/27
Most frequent other events
Showing 10 of 42
Most frequent other events
EventTemozolomide TreatmentObservation
FATIGUEGeneral disorders15/264/27
NAUSEAGastrointestinal disorders13/265/27
COUGHRespiratory, thoracic and mediastinal disorders7/267/27
VOMITINGGastrointestinal disorders6/262/27
BACK PAINMusculoskeletal and connective tissue disorders6/264/27
DIARRHOEAGastrointestinal disorders5/264/27
DECREASED APPETITEMetabolism and nutrition disorders5/264/27
DIZZINESSNervous system disorders5/261/27
DEPRESSIONPsychiatric disorders1/265/27
LYMPHOPENIABlood and lymphatic system disorders4/260/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Temozolomide TreatmentObservationTotal
Mean64.8 ± 9.465.1 ± 10.865.0 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Temozolomide TreatmentObservationTotal
Female121123
Male141630
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Boggs DH, Robins HI, Langer CJ, Traynor AM, Berkowitz MJ, Mehta MP. Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation. Clin Lung Cancer. 2014 Nov;15(6):433-40. doi: 10.1016/j.cllc.2014.06.008. Epub 2014 Jun 24. PubMed 25069747 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2008 to primary completion in Jan 2011, 34 months.

Results were first posted in Mar 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2008
First posted
Mar 10, 2008
StartActual
Mar 4, 2008
Primary completionActual
Jan 6, 2011
CompletionActual
Jan 7, 2011
Results first posted
Mar 26, 2012
Last update
Jun 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00632203
Responsible party
Sponsor
First posted
Mar 10, 2008
Start date
Mar 4, 2008
Primary completion
Jan 6, 2011
Completion
Jan 7, 2011
Results posted
Mar 26, 2012
Last update
Jun 7, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion